The bnp and ntprobnp market size has grown rapidly in recent years. It will grow from $2.01 billion in 2024 to $2.26 billion in 2025 at a compound annual growth rate (CAGR) of 12.6%. The growth in the historic period can be attributed to aging population, clinical utility in heart failure diagnosis, advancements in cardiovascular medicine, focus on preventive healthcare.
The bnp and ntprobnp market size is expected to see rapid growth in the next few years. It will grow to $3.6 billion in 2029 at a compound annual growth rate (CAGR) of 12.3%. The growth in the forecast period can be attributed to increasing cardiovascular disease burden, integration into point-of-care testing, expanding applications in other medical conditions, personalized medicine approaches, telemedicine and remote monitoring. Major trends in the forecast period include technological advancements in assay methods, personalized medicine approaches, biomarker in predicting prognosis, emergence of novel biomarkers, global standardization efforts.
The increasing occurrence of cardiovascular diseases is anticipated to drive the growth of the BNP and NTproBNP market in the future. Cardiovascular diseases encompass conditions that impact the heart and blood vessels, including peripheral arterial disease, cerebrovascular disease, and coronary heart disease, among others. Tests for BNP and NTproBNP focus on monitoring heart health and safety, identifying factors that contribute to cardiovascular disease prior to its onset, which aids in implementing preventive measures and lowering the risk of mortality. For example, in May 2024, the Centers for Disease Control and Prevention (CDC), a government agency in the US, reported that a death related to cardiovascular disease occurs every 33 seconds, with heart disease accounting for 702,880 deaths in 2022 - roughly one in five fatalities. The growing incidence of cardiovascular diseases is propelling the BNP and NTproBNP markets.
The expanding geriatric demographic is anticipated to be a driving force for the BNP and NTproBNP market's expansion. This segment, comprising individuals aged 65 or older, finds critical assistance from BNP and NTproBNP tests in diagnosing and managing heart failure. These biomarkers provide valuable insights into cardiac function, aiding in tailored treatment strategies for elderly individuals. The World Health Organization reports that by 2030, one in six individuals globally will be 60 or older, projected to reach 2.1 billion elderly individuals by 2050. Hence, the burgeoning geriatric population propels the growth of the BNP and NTproBNP market.
Innovation in product development emerges as a significant trend driving the BNP and NTproBNP markets. Leading companies in these markets prioritize introducing novel products to maintain their market positions. For instance, in May 2023, Randox Laboratories unveiled a BNP1-32 diagnostic test for heart failure diagnosis. This automated test measures BNP levels with high sensitivity and specificity, integrating with third-party controls and software for effective QC data monitoring. This control ensures accurate and reliable BNP testing.
Prominent companies in the BNP and NTproBNP market are intensifying their focus on rapid screening bioassays to gain a competitive edge. Rapid screening bioassays efficiently assess substance presence or concentration by measuring effects on living cells or organisms, aiding in swift and reliable attribute identification or condition categorization. Mindray Medical International Limited, in October 2023, introduced two new assays - high-sensitivity troponin I (hs-cTnI) and N-terminal pro-B-type natriuretic peptide (NT-proBNP). These assays bolster Mindray's ability to screen, risk-stratify, diagnose rapidly, and monitor therapy for cardiovascular diseases, enhancing their portfolio for efficient disease management. Mindray's collaboration with HyTest further strengthens its immunoassay platforms, integrating advanced research and antibodies for cardiac biomarkers.
In July 2024, Roche Holding AG, a pharmaceutical and diagnostics company based in Switzerland, acquired LumiraDx Limited for an undisclosed sum. This acquisition is intended to strengthen Roche's diagnostics portfolio by incorporating advanced point-of-care technology that facilitates quick testing for BNP and NT-proBNP. LumiraDx Limited, located in the UK, is known for its innovative rapid test for NT-proBNP.
Major companies operating in the bnp and ntprobnp market include Abbott Laboratories, Gentian Diagnostics ASA, Siemens AG, PerkinElmer Inc., Biomerieux SA, Quidel Corporation, Bio-Rad Laboratories Inc., F Hoffman La Roche Ltd., CTK Biotech Inc., RayBiotech Life Inc., BHR Pharmaceuticals Ltd., Getein Biotech Inc., VACURE Biotechnology Co. Ltd., Bio-Techne Co., Xiamen Biotime Biotechnology Co. Ltd., Scripps Laboratories Inc., Danaher Corporation, Beckman Coulter Inc., Thermo Fisher Scientific Inc., Randox Laboratories Ltd., LSI Medience Corporation, Shionogi & Co. Ltd., Radiometer Medical ApS, Ortho Clinical Diagnostics, Tosoh Corporation, Aidian Oy, Shenzhen Mindray Bio-Medical Electronics Co. Ltd., Becton Dickinson and Company, Acon Laboratories Inc., Response Biomedical Corp., Nanomix Inc., Cepheid Inc., Alere Inc.
Asia-Pacific was the largest region in the BNP and NTproBNP market in 2024. North America is expected to be the fastest-growing region in the global BNP and NTproBNP market report during the forecast period. The regions covered in the bnp and ntprobnp market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the bnp and ntprobnp market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
BNP (B-type natriuretic peptide) and NT-proBNP (N-terminal Pro-brain Natriuretic Peptide) tests are diagnostic assessments gauging the levels of either BNP or its precursor hormone NT-proBNP in the blood. These tests serve as indicators for heart failure and various cardiac conditions. BNP and NT-proBNP, categorized as natriuretic peptides, hold pivotal roles in regulating circulation. Elevated levels of BNP or NT-proBNP typically signify underlying heart disease, specifically abnormalities in blood pumping.
These tests primarily involve measuring the quantities of BNP (brain natriuretic peptide) and NT-proBNP (N-terminal pro-B-type natriuretic peptide) in the bloodstream. The BNP test specifically targets BNP levels, aiding in the detection of heart failure and other cardiac conditions. Testing locations encompass both point-of-care and laboratory settings, facilitating diagnostics for myocardial infarction, congestive heart failure, acute coronary syndrome (ACS), and other related ailments.
The BNP and NTproBNP market research report is one of a series of new reports that provides BNP and NTproBNP market statistics, including the BNP and NTproBNP industry global market size, regional shares, competitors with a BNP and NTproBNP market share, detailed BNP and NTproBNP market segments, market trends, and opportunities, and any further data you may need to thrive in the BNP and NTproBNP industry. This BNP and NTproBNP market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.
The BNP and NTproBNP market includes revenues earned by companies by providing diagnostic and heart disease detection services using BNP (B-type natriuretic peptide) or NT-proBNP (N-terminal Pro-brain Natriuretic Peptide) as biomarkers, BNP and NTproBNP assays. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
This product will be delivered within 3-5 business days.
The bnp and ntprobnp market size is expected to see rapid growth in the next few years. It will grow to $3.6 billion in 2029 at a compound annual growth rate (CAGR) of 12.3%. The growth in the forecast period can be attributed to increasing cardiovascular disease burden, integration into point-of-care testing, expanding applications in other medical conditions, personalized medicine approaches, telemedicine and remote monitoring. Major trends in the forecast period include technological advancements in assay methods, personalized medicine approaches, biomarker in predicting prognosis, emergence of novel biomarkers, global standardization efforts.
The increasing occurrence of cardiovascular diseases is anticipated to drive the growth of the BNP and NTproBNP market in the future. Cardiovascular diseases encompass conditions that impact the heart and blood vessels, including peripheral arterial disease, cerebrovascular disease, and coronary heart disease, among others. Tests for BNP and NTproBNP focus on monitoring heart health and safety, identifying factors that contribute to cardiovascular disease prior to its onset, which aids in implementing preventive measures and lowering the risk of mortality. For example, in May 2024, the Centers for Disease Control and Prevention (CDC), a government agency in the US, reported that a death related to cardiovascular disease occurs every 33 seconds, with heart disease accounting for 702,880 deaths in 2022 - roughly one in five fatalities. The growing incidence of cardiovascular diseases is propelling the BNP and NTproBNP markets.
The expanding geriatric demographic is anticipated to be a driving force for the BNP and NTproBNP market's expansion. This segment, comprising individuals aged 65 or older, finds critical assistance from BNP and NTproBNP tests in diagnosing and managing heart failure. These biomarkers provide valuable insights into cardiac function, aiding in tailored treatment strategies for elderly individuals. The World Health Organization reports that by 2030, one in six individuals globally will be 60 or older, projected to reach 2.1 billion elderly individuals by 2050. Hence, the burgeoning geriatric population propels the growth of the BNP and NTproBNP market.
Innovation in product development emerges as a significant trend driving the BNP and NTproBNP markets. Leading companies in these markets prioritize introducing novel products to maintain their market positions. For instance, in May 2023, Randox Laboratories unveiled a BNP1-32 diagnostic test for heart failure diagnosis. This automated test measures BNP levels with high sensitivity and specificity, integrating with third-party controls and software for effective QC data monitoring. This control ensures accurate and reliable BNP testing.
Prominent companies in the BNP and NTproBNP market are intensifying their focus on rapid screening bioassays to gain a competitive edge. Rapid screening bioassays efficiently assess substance presence or concentration by measuring effects on living cells or organisms, aiding in swift and reliable attribute identification or condition categorization. Mindray Medical International Limited, in October 2023, introduced two new assays - high-sensitivity troponin I (hs-cTnI) and N-terminal pro-B-type natriuretic peptide (NT-proBNP). These assays bolster Mindray's ability to screen, risk-stratify, diagnose rapidly, and monitor therapy for cardiovascular diseases, enhancing their portfolio for efficient disease management. Mindray's collaboration with HyTest further strengthens its immunoassay platforms, integrating advanced research and antibodies for cardiac biomarkers.
In July 2024, Roche Holding AG, a pharmaceutical and diagnostics company based in Switzerland, acquired LumiraDx Limited for an undisclosed sum. This acquisition is intended to strengthen Roche's diagnostics portfolio by incorporating advanced point-of-care technology that facilitates quick testing for BNP and NT-proBNP. LumiraDx Limited, located in the UK, is known for its innovative rapid test for NT-proBNP.
Major companies operating in the bnp and ntprobnp market include Abbott Laboratories, Gentian Diagnostics ASA, Siemens AG, PerkinElmer Inc., Biomerieux SA, Quidel Corporation, Bio-Rad Laboratories Inc., F Hoffman La Roche Ltd., CTK Biotech Inc., RayBiotech Life Inc., BHR Pharmaceuticals Ltd., Getein Biotech Inc., VACURE Biotechnology Co. Ltd., Bio-Techne Co., Xiamen Biotime Biotechnology Co. Ltd., Scripps Laboratories Inc., Danaher Corporation, Beckman Coulter Inc., Thermo Fisher Scientific Inc., Randox Laboratories Ltd., LSI Medience Corporation, Shionogi & Co. Ltd., Radiometer Medical ApS, Ortho Clinical Diagnostics, Tosoh Corporation, Aidian Oy, Shenzhen Mindray Bio-Medical Electronics Co. Ltd., Becton Dickinson and Company, Acon Laboratories Inc., Response Biomedical Corp., Nanomix Inc., Cepheid Inc., Alere Inc.
Asia-Pacific was the largest region in the BNP and NTproBNP market in 2024. North America is expected to be the fastest-growing region in the global BNP and NTproBNP market report during the forecast period. The regions covered in the bnp and ntprobnp market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the bnp and ntprobnp market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
BNP (B-type natriuretic peptide) and NT-proBNP (N-terminal Pro-brain Natriuretic Peptide) tests are diagnostic assessments gauging the levels of either BNP or its precursor hormone NT-proBNP in the blood. These tests serve as indicators for heart failure and various cardiac conditions. BNP and NT-proBNP, categorized as natriuretic peptides, hold pivotal roles in regulating circulation. Elevated levels of BNP or NT-proBNP typically signify underlying heart disease, specifically abnormalities in blood pumping.
These tests primarily involve measuring the quantities of BNP (brain natriuretic peptide) and NT-proBNP (N-terminal pro-B-type natriuretic peptide) in the bloodstream. The BNP test specifically targets BNP levels, aiding in the detection of heart failure and other cardiac conditions. Testing locations encompass both point-of-care and laboratory settings, facilitating diagnostics for myocardial infarction, congestive heart failure, acute coronary syndrome (ACS), and other related ailments.
The BNP and NTproBNP market research report is one of a series of new reports that provides BNP and NTproBNP market statistics, including the BNP and NTproBNP industry global market size, regional shares, competitors with a BNP and NTproBNP market share, detailed BNP and NTproBNP market segments, market trends, and opportunities, and any further data you may need to thrive in the BNP and NTproBNP industry. This BNP and NTproBNP market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.
The BNP and NTproBNP market includes revenues earned by companies by providing diagnostic and heart disease detection services using BNP (B-type natriuretic peptide) or NT-proBNP (N-terminal Pro-brain Natriuretic Peptide) as biomarkers, BNP and NTproBNP assays. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
This product will be delivered within 3-5 business days.
Table of Contents
1. Executive Summary2. BNP and NTproBNP Market Characteristics3. BNP and NTproBNP Market Trends and Strategies4. BNP and NTproBNP Market - Macro Economic Scenario including the impact of Interest Rates, Inflation, Geopolitics and Covid and Recovery on the Market32. Global BNP and NTproBNP Market Competitive Benchmarking and Dashboard33. Key Mergers and Acquisitions in the BNP and NTproBNP Market34. Recent Developments in the BNP and NTproBNP Market
5. Global BNP and NTproBNP Growth Analysis and Strategic Analysis Framework
6. BNP and NTproBNP Market Segmentation
7. BNP and NTproBNP Market Regional and Country Analysis
8. Asia-Pacific BNP and NTproBNP Market
9. China BNP and NTproBNP Market
10. India BNP and NTproBNP Market
11. Japan BNP and NTproBNP Market
12. Australia BNP and NTproBNP Market
13. Indonesia BNP and NTproBNP Market
14. South Korea BNP and NTproBNP Market
15. Western Europe BNP and NTproBNP Market
16. UK BNP and NTproBNP Market
17. Germany BNP and NTproBNP Market
18. France BNP and NTproBNP Market
19. Italy BNP and NTproBNP Market
20. Spain BNP and NTproBNP Market
21. Eastern Europe BNP and NTproBNP Market
22. Russia BNP and NTproBNP Market
23. North America BNP and NTproBNP Market
24. USA BNP and NTproBNP Market
25. Canada BNP and NTproBNP Market
26. South America BNP and NTproBNP Market
27. Brazil BNP and NTproBNP Market
28. Middle East BNP and NTproBNP Market
29. Africa BNP and NTproBNP Market
30. BNP and NTproBNP Market Competitive Landscape and Company Profiles
31. BNP and NTproBNP Market Other Major and Innovative Companies
35. BNP and NTproBNP Market High Potential Countries, Segments and Strategies
36. Appendix
Executive Summary
BNP and NTproBNP Global Market Report 2025 provides strategists, marketers and senior management with the critical information they need to assess the market.This report focuses on bnp and ntprobnp market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.
Reasons to Purchase:
- Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
- Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
- Create regional and country strategies on the basis of local data and analysis.
- Identify growth segments for investment.
- Outperform competitors using forecast data and the drivers and trends shaping the market.
- Understand customers based on the latest market shares.
- Benchmark performance against key competitors.
- Suitable for supporting your internal and external presentations with reliable high quality data and analysis
- Report will be updated with the latest data and delivered to you along with an Excel data sheet for easy data extraction and analysis.
- All data from the report will also be delivered in an excel dashboard format.
Description
Where is the largest and fastest growing market for bnp and ntprobnp? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The bnp and ntprobnp market global report answers all these questions and many more.The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market’s historic and forecast market growth by geography.
- The market characteristics section of the report defines and explains the market.
- The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
- The forecasts are made after considering the major factors currently impacting the market. These include:
- The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.
- Market segmentations break down the market into sub markets.
- The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
- The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
- The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.
Scope
Markets Covered:
1) By Type: BNP (Brain Natriuretic Peptide); NT-proBNP (N-terminal Pro-B-Type Natriuretic Peptide)2) By Location of Testing: Point of Care Testing; Laboratory Testing
3) By Application: Myocardial Infarction; Congestive Heart Failure; Acute Coronary Syndrome (ACS); Other Applications
Subsegments:
1) By BNP (Brain Natriuretic Peptide): BNP Testing Kits; Point-of-Care BNP Testing Devices; Laboratory BNP Assays2) By NT-ProBNP (N-Terminal Pro-B-Type Natriuretic Peptide): NT-ProBNP Testing Kits; Point-of-Care NT-proBNP Testing Devices; Laboratory NT-ProBNP Assays
Key Companies Mentioned: Abbott Laboratories; Gentian Diagnostics ASA; Siemens AG; PerkinElmer Inc.; Biomerieux SA
Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
Time Series: Five years historic and ten years forecast.
Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita.
Data Segmentation: Country and regional historic and forecast data, market share of competitors, market segments.
Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
Delivery Format: PDF, Word and Excel Data Dashboard.
Companies Mentioned
- Abbott Laboratories
- Gentian Diagnostics ASA
- Siemens AG
- PerkinElmer Inc.
- Biomerieux SA
- Quidel Corporation
- Bio-Rad Laboratories Inc.
- F Hoffman La Roche Ltd.
- CTK Biotech Inc.
- RayBiotech Life Inc.
- BHR Pharmaceuticals Ltd.
- Getein Biotech Inc.
- VACURE Biotechnology Co. Ltd.
- Bio-Techne Co.
- Xiamen Biotime Biotechnology Co. Ltd.
- Scripps Laboratories Inc.
- Danaher Corporation
- Beckman Coulter Inc.
- Thermo Fisher Scientific Inc.
- Randox Laboratories Ltd.
- LSI Medience Corporation
- Shionogi & Co. Ltd.
- Radiometer Medical ApS
- Ortho Clinical Diagnostics
- Tosoh Corporation
- Aidian Oy
- Shenzhen Mindray Bio-Medical Electronics Co. Ltd.
- Becton Dickinson and Company
- Acon Laboratories Inc.
- Response Biomedical Corp.
- Nanomix Inc.
- Cepheid Inc.
- Alere Inc.
Table Information
| Report Attribute | Details |
|---|---|
| No. of Pages | 200 |
| Published | February 2025 |
| Forecast Period | 2025 - 2029 |
| Estimated Market Value ( USD | $ 2.26 Billion |
| Forecasted Market Value ( USD | $ 3.6 Billion |
| Compound Annual Growth Rate | 12.3% |
| Regions Covered | Global |
| No. of Companies Mentioned | 33 |
